Cargando…

Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials

BACKGROUND: To evaluate whether patients of varying ages and lung function with asthma or those with chronic obstructive pulmonary disease (COPD) can achieve sufficient inspiratory flows for effective use of the fixed-dose combination of salmeterol-fluticasone propionate and budesonide-formoterol di...

Descripción completa

Detalles Bibliográficos
Autores principales: Malmberg, L. Pekka, Pelkonen, Anna S., Vartiainen, Ville, Vahteristo, Mikko, Lähelmä, Satu, Jõgi, Rain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947512/
https://www.ncbi.nlm.nih.gov/pubmed/33717535
http://dx.doi.org/10.21037/jtd-20-2112
_version_ 1783663244929400832
author Malmberg, L. Pekka
Pelkonen, Anna S.
Vartiainen, Ville
Vahteristo, Mikko
Lähelmä, Satu
Jõgi, Rain
author_facet Malmberg, L. Pekka
Pelkonen, Anna S.
Vartiainen, Ville
Vahteristo, Mikko
Lähelmä, Satu
Jõgi, Rain
author_sort Malmberg, L. Pekka
collection PubMed
description BACKGROUND: To evaluate whether patients of varying ages and lung function with asthma or those with chronic obstructive pulmonary disease (COPD) can achieve sufficient inspiratory flows for effective use of the fixed-dose combination of salmeterol-fluticasone propionate and budesonide-formoterol dispensed with the Easyhaler(®) (EH) device-metered, multi-dose dry powder inhaler (DPI). METHODS: A pooled analysis of two randomized, multicenter, crossover, open-label studies (NCT01424137; NCT009849061) was conducted to characterize inspiratory flow parameters across the EH, Seretide Diskus (DI) and Symbicort Turbuhaler (TH) inhalers in patients with asthma and/or COPD of varying severity. The primary endpoint was peak inspiratory flow (PIF) rate through the EH. RESULTS: The intent-to-treat population comprised 397 patients; 383 patients were included in the per-protocol (PP) population. The mean PIF (standard deviation) values through the EH in patients <18 and ≥18 years of age with asthma and in those with COPD, were similar: 61.4 (11.5), 69.7 (13.5), and 61.9 (13.2) L/min, respectively. These flow rates correspond to pressure drops of 5.05 (1.80), 6.52 (2.34) and 5.19 (2.07) kPa, respectively. In total, 380 (99.2%) of patients in the PP population were able to generate a PIF rate through the EH of ≥30 L/min, which is required to enable consistent dose delivery from the DPI; there was a moderate direct association between age and PIF in younger patients with asthma, but this was inverse and less apparent in adult patients with asthma and/or those with COPD. Height and weight were also moderately correlated with PIF. Stronger associations with PIF were observed for some lung function parameters, particularly native PIF and forced inspiratory vital capacity. CONCLUSIONS: Over 99% of patients with asthma and/or COPD were able to inhale through the EH with an adequate PIF rate, irrespective of age, or severity of airway obstruction. This confirms that patients with asthma and/or COPD can achieve inspiratory flows via the EH DPI that are sufficient for its effective use.
format Online
Article
Text
id pubmed-7947512
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79475122021-03-12 Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials Malmberg, L. Pekka Pelkonen, Anna S. Vartiainen, Ville Vahteristo, Mikko Lähelmä, Satu Jõgi, Rain J Thorac Dis Original Article BACKGROUND: To evaluate whether patients of varying ages and lung function with asthma or those with chronic obstructive pulmonary disease (COPD) can achieve sufficient inspiratory flows for effective use of the fixed-dose combination of salmeterol-fluticasone propionate and budesonide-formoterol dispensed with the Easyhaler(®) (EH) device-metered, multi-dose dry powder inhaler (DPI). METHODS: A pooled analysis of two randomized, multicenter, crossover, open-label studies (NCT01424137; NCT009849061) was conducted to characterize inspiratory flow parameters across the EH, Seretide Diskus (DI) and Symbicort Turbuhaler (TH) inhalers in patients with asthma and/or COPD of varying severity. The primary endpoint was peak inspiratory flow (PIF) rate through the EH. RESULTS: The intent-to-treat population comprised 397 patients; 383 patients were included in the per-protocol (PP) population. The mean PIF (standard deviation) values through the EH in patients <18 and ≥18 years of age with asthma and in those with COPD, were similar: 61.4 (11.5), 69.7 (13.5), and 61.9 (13.2) L/min, respectively. These flow rates correspond to pressure drops of 5.05 (1.80), 6.52 (2.34) and 5.19 (2.07) kPa, respectively. In total, 380 (99.2%) of patients in the PP population were able to generate a PIF rate through the EH of ≥30 L/min, which is required to enable consistent dose delivery from the DPI; there was a moderate direct association between age and PIF in younger patients with asthma, but this was inverse and less apparent in adult patients with asthma and/or those with COPD. Height and weight were also moderately correlated with PIF. Stronger associations with PIF were observed for some lung function parameters, particularly native PIF and forced inspiratory vital capacity. CONCLUSIONS: Over 99% of patients with asthma and/or COPD were able to inhale through the EH with an adequate PIF rate, irrespective of age, or severity of airway obstruction. This confirms that patients with asthma and/or COPD can achieve inspiratory flows via the EH DPI that are sufficient for its effective use. AME Publishing Company 2021-02 /pmc/articles/PMC7947512/ /pubmed/33717535 http://dx.doi.org/10.21037/jtd-20-2112 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Malmberg, L. Pekka
Pelkonen, Anna S.
Vartiainen, Ville
Vahteristo, Mikko
Lähelmä, Satu
Jõgi, Rain
Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title_full Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title_fullStr Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title_full_unstemmed Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title_short Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
title_sort patients with asthma or chronic obstructive pulmonary disease (copd) can generate sufficient inspiratory flows via easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947512/
https://www.ncbi.nlm.nih.gov/pubmed/33717535
http://dx.doi.org/10.21037/jtd-20-2112
work_keys_str_mv AT malmberglpekka patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials
AT pelkonenannas patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials
AT vartiainenville patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials
AT vahteristomikko patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials
AT lahelmasatu patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials
AT jogirain patientswithasthmaorchronicobstructivepulmonarydiseasecopdcangeneratesufficientinspiratoryflowsviaeasyhalerdrypowderinhalerapooledanalysisoftworandomizedcontrolledtrials